The Gl Genetics Core will serve a critical role in facilitating access to genetic tools for Center-based research projects. Genetic manipulation is a critical approach from biological modeling to establishing and testing critical molecular signaling pathways in both the normal and clinically relevant disease state. Genetic tools are extremely dynamic, with new technologies coming on line every year. The Genetics Core will serve as a hub for current, emerging and future genetic technologies, advising and helping Center members properly assess and keep abreast of these often disruptive scientific advances. The Genetics Core will balance its efforts on current (such as siRNA, in vivo imaging, microarray, mouse ES cells), emerging (such as transcriptome analyses via next-generation sequencing and zebrafish knockouts) and near-future (such as new DNA delivery platforms including silica nanopartides) genetics tools. As a hub for access to the latest information on genetics technologies, this core will represent an important and central interface to this dynamic research area through its training opportunities, Web site and individual consultation. The Genetics Core Director (Stephen C. Ekker, Ph.D., 15% time requested) is a recent recruit to the Mayo Clinic with extensive molecular genetics expertise. To achieve the goal of this Core, part-time support for bioinformatics, biostatistics and genetics instruction is requested.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK084567-03
Application #
8309302
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
3
Fiscal Year
2011
Total Cost
$228,125
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Rizvi, Sumera; Fischbach, Samantha R; Bronk, Steven F et al. (2018) YAP-associated chromosomal instability and cholangiocarcinoma in mice. Oncotarget 9:5892-5905
Anderson, Bradley W; Suh, Yun-Suhk; Choi, Boram et al. (2018) Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma. Clin Cancer Res 24:5724-5734
Rizvi, Sumera; Khan, Shahid A; Hallemeier, Christopher L et al. (2018) Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15:95-111
Mouchli, Mohamad A; Ouk, Lidia; Scheitel, Marianne R et al. (2018) Colonoscopy surveillance for high risk polyps does not always prevent colorectal cancer. World J Gastroenterol 24:905-916
Allen, Alina M; Therneau, Terry M; Larson, Joseph J et al. (2018) Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology 67:1726-1736
Hale, Vanessa L; Jeraldo, Patricio; Chen, Jun et al. (2018) Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers. Genome Med 10:78
Strege, Peter R; Mazzone, Amelia; Bernard, Cheryl E et al. (2018) Irritable bowel syndrome patients have SCN5A channelopathies that lead to decreased NaV1.5 current and mechanosensitivity. Am J Physiol Gastrointest Liver Physiol 314:G494-G503
Rizvi, Sumera; Eaton, John; Yang, Ju Dong et al. (2018) Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma. Semin Liver Dis 38:160-169
Druliner, Brooke R; Ruan, Xiaoyang; Sicotte, Hugues et al. (2018) Early genetic aberrations in patients with sporadic colorectal cancer. Mol Carcinog 57:114-124

Showing the most recent 10 out of 537 publications